ACR Guidelines on New Treatment Paradigms for SLE

Program Overview

In this educational program, Dr. Maria Dall’Era will discuss the clinical implications of the updated American College of Rheumatology (ACR) recommendations for the management of systemic lupus erythematosus (SLE). Dr. Dall’Era will highlight specific detailed information, sharing her opinions regarding the role of biologic therapies in individualizing treatment regimens with the goal of reducing glucocorticoid use while minimizing flares and organ damage.

Educational Objectives 

After completing this activity, the participant should be better able to:

1. Implement new guideline recommendations on regularly monitoring patients with SLE, including evaluations of disease activity measures, organ damage, and patient-reported outcomes
2. Describe recent guidelines on the use of biologic therapies for patients with moderate-to-severe SLE
3. Individualize steroid-sparing treatment regimens for patients with moderate-to-severe SLE based on clinical manifestations, risks, treatment goals, and shared decision making

Target Audience

This educational activity will provide continuing medical education (CME) to clinicians who manage patients with SLE, including rheumatologists, internal medicine physicians, and specialist nurse practitioners (NPs) and physician associates (PAs). 

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com. 

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Maria Dall’Era, MD: 

Consulting Fees (eg, advisory boards): AstraZeneca plc, Aurinia Pharmaceuticals Inc., Biogen Inc., Genentech, Inc., GSK plc

The Integritas planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.